Holen Sie sich die Stockscreener-App
2.51
0.40%
0.010
Handel nachbörslich:
2.56
0.05
+1.99%
Schlusskurs vom Vortag:
$2.50
Offen:
$2.5
24-Stunden-Volumen:
60,795
Relative Volume:
1.23
Marktkapitalisierung:
$34.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.18%
1M Leistung:
-19.81%
6M Leistung:
-85.75%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.44
$2.54
1-Wochen-Bereich:
$2.42
$2.65
52-Wochen-Spanne:
$2.42
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Vergleichen Sie OKUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.51 | 34.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
Renaissance Technologies LLC Invests $408,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages - Defense World
Geode Capital Management LLC Makes New $659,000 Investment in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Q1 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
OnKure Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating - marketscreener.com
Evercore ISI starts OnKure stock with Outperform rating - Investing.com
Evercore ISI starts OnKure stock with Outperform rating By Investing.com - Investing.com India
OKUR stock touches 52-week low at $2.49 amid market challenges - Investing.com
OnKure Therapeutics CEO sells $2,569 in stock - Investing.com Australia
OnKure Therapeutics CFO sells $9,177 in stock By Investing.com - Investing.com South Africa
OnKure Therapeutics CEO sells $2,569 in stock By Investing.com - Investing.com India
OnKure Therapeutics CFO sells $9,177 in stock - Investing.com
OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com Canada
OKUR stock touches 52-week low at $3.39 amid market challenges By Investing.com - Investing.com South Africa
We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia
OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World
H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks
H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Onkure discovers new PI3Kα inhibitors - BioWorld Online
What is Lifesci Capital’s Estimate for OKUR FY2025 Earnings? - Defense World
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects - TipRanks
Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely? - Yahoo Finance
OnKure Therapeutics (NASDAQ:OKUR) Given New $30.00 Price Target at Oppenheimer - Defense World
OnKure Therapeutics Reports Progress and Financials - TipRanks
OnKure boosts R&D spending with cancer trial underway - BizWest
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating - Marketscreener.com
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer - TipRanks
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c) - TipRanks
OnKure Therapeutics, Inc. SEC 10-K Report - TradingView
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences - GlobeNewswire
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 4.7% – Time to Sell? - Defense World
FY2025 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - Nasdaq
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Es liegen keine Finanzdaten für Onkure Therapeutics Inc (OKUR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):